Almac Discovery announces Two Vice President Appointments
Almac Discovery, a research driven drug discovery company and member of the Almac Group, has announced the appointment of two new Vice Presidents.
Graham Cotton has been appointed to the position of Vice President, Protein Therapeutics and Colin O’Dowd to the position of Vice President, Medicinal Chemistry.
Stephen Barr, President and Managing Director of Almac Discovery commented: “Graham is an internationally recognised expert in protein and peptide drug development and has been a key contributor to the development of the Almac Discovery protein-drug conjugate (PDC) platform, which is now poised to deliver multiple First in Class and Best in Class projects.
“Colin has an outstanding knowledge of synthetic and medicinal chemistry and has developed an enviable track record of delivery across all phases of preclinical drug discovery. He has been a key contributor to development of Almac Discovery’s UbiPlexTM platform, focused on modulation of deubiquitinase enzymes to manipulate the ubiquitin-proteasome system.”
Dewpoint Therapeutics partners with Novo Nordisk to explore the field of biomolecular condensates to treat insulin resistance and diabetes progression
BIAL appoints Max Bricchi as Chief Commercial Officer
BenevolentAI strengthens its Board of Directors with the appointment of digital innovation expert Marcello Damiani